- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03353961
Internet Delivered ERITA for Nonsuicidal Self-Injury (ERITA)
Internet Delivered Emotion Regulation Individual Therapy for Adolescents With Nonsuicidal Self-Injury: A Randomized Controlled Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Statistical Analyses
Treatment effects will be evaluated according to the intention-to-treat principle. Primary end-point for all outcomes is post-treatment. Secondary end-point include a controlled 3 month follow-up.
Primary Analysis
The primary outcome analysis will include treatment group (ERITA , TAU) and weekly reports of NSSI frequency measured once every week 4 weeks prior to treatment start, once every week during treatment, and once every week four weeks after treatment termination. Regression analysis modelled for count data will be used to estimate trend over time. Four weeks after treatment termination will be considered primary endpoint. Pairwise contrasts (group x time interaction) from the regression model will be used to evaluate between-group differences at primary endpoint (4 weeks after treatment termination).
Secondary Analyses
Secondary outcomes measured once before, during, and after treatment will be analyzed in a similar fashion as for the primary outcome, modelled after data's distribution (count or continuous). Measures collected only once at baseline and post-treatment will be analyzed with regression analyses including treatment group (online ERITA , TAU) as the between-subjects factor, time (baseline to post) as the within-subjects factor, and group × time interactions, modelled after data's distribution (count or continuous).
Parallel process latent growth curve modeling will be used to determine whether change in week-to-week emotion dysregulation (DERS-16) during treatment mediate the overall effect of ERITA+ETAU on week-to-week change in the primary outcome self-rated NSSI frequency (DSHI-Y).
3 Month Follow-Up
Data collected at 3-month follow-up will be used to determine the extent to which potential treatment gains were maintained both within and between treatment conditions
Update 28 April 2022: As a secondary analyses, we also aim to investigate the effect of treatment moderators (primary aim) and predictors (secondary aim) on NSSI frequency one month after treatment termination. This update was submitted prior to conducting the analyses.
The selection of potential moderators was theoretically and empirically motivated. We will investigate the following variables (measured at baseline):
Age Difficulties in emotion regulation As measured with the Difficulties in Emotion Regulation Scale - 36 item version (DERS) Past month NSSI frequency As measured with the Deliberate Self-Harm Inventory Youth version (DSHI-Y) Global functioning As measured with the Childrens Global Assessment Scale Depressive symptoms As measured with the 21-item Depression Anxiety Stress Scales (DASS-21) Sleep difficulties As measured with the Insomnia Severity Index (ISI) Parental Minimization - discounting or devaluing the child's negative emotions/problems As measured with The Coping with Children's Negative Emotions Scale Adolescent Version (CCNES-A), subscale minimazation Level of suicidality As measured with the MINI-KID International Neuropsychiatric Interview, version 6
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden, 113 64
- Centre for Psychiatry Research Karolinska Institutet and Stockholm County Council
-
Stockholm, Sweden, 113 64
- Karolinska Institutet
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ≥ 5 nonsuicidal self-injury episodes past year
- ≥ 1 nonsuicidal self-injury episodes past month
- having at least one parent who committed to participate in the parent program
Exclusion Criteria:
- Severe suicidal ideation
- a diagnosis of psychotic or bipolar I disorder or ongoing (past month) substance dependence
- the presence of co-occurring psychological disorders that required immediate treatment (i.e., severe anorexia nervosa)
- insufficient understanding of the Swedish language
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Adjunctive Internet-delivered ERITA
Participants will receive 11 weeks of internet-delivered emotion regulation individual therapy with therapist support adjunctive to treatment as usual as provided in the community.
The caregiver(s) will receive 6 modules of internet-delivered parent program with therapist support.
|
The emotion regulation individual therapy is delivered via an internet platform and includes therapist contact several times per week via the platform.
|
|
Active Comparator: Treatment as usual
Participants will receive treatment as usual for 11 weeks of treatment as usual as provided in the community.
|
Treatment as usual as provided in the community.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Deliberate Self-Harm Inventory Youth version (DSHI-Y)
Time Frame: Change from baseline, once every week during treatment (0-12 weeks after baseline), 3 and 12 months after treatment has ended
|
Frequency of nonsuicidal self-injury
|
Change from baseline, once every week during treatment (0-12 weeks after baseline), 3 and 12 months after treatment has ended
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difficulties in Emotion Regulation Scale - 16 item version (DERS-16)
Time Frame: Change from baseline, once every week during treatment (0-12 weeks after baseline), 3 and 12 months after treatment has ended
|
Difficulties in emotion regulation as primary potential mechanism of change.
Ranges from 16-80, with higher scores indicating more difficulties.
|
Change from baseline, once every week during treatment (0-12 weeks after baseline), 3 and 12 months after treatment has ended
|
|
Difficulties in Emotion Regulation Scale - 36 item version (DERS)
Time Frame: Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended
|
Difficulties in emotion regulation.
Ranges from 36-180, with higher scores indicating more difficulties.
|
Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended
|
|
the 21-item Depression Anxiety Stress Scales (DASS-21)
Time Frame: Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended
|
Symptoms of depression, anxiety and stress.
Each subscale (depression, anxiety and stress) ranges from 0-21, with higher scores indicating more symptoms.
|
Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended
|
|
Borderline Symptom List Supplement
Time Frame: Change from baseline, once every week during treatment (0-12 weeks after baseline), 3 and 12 months after treatment has ended
|
Impulsive self-destructive behaviors
|
Change from baseline, once every week during treatment (0-12 weeks after baseline), 3 and 12 months after treatment has ended
|
|
Acceptance and Action Questionnaire
Time Frame: Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended
|
Acceptance and valued actions.
Ranges from 7-49, with higher scores indicating less acceptance and valued actions.
|
Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended
|
|
Childrens Global Assessment Scale
Time Frame: Change from baseline, 16 weeks after treatment starts, 3 months after treatment has ended
|
Global functioning.
Ranges from 1-100, with higher scores indicating better functioning.
|
Change from baseline, 16 weeks after treatment starts, 3 months after treatment has ended
|
|
The Clinical Global Impressions -Severity and Improvement scales
Time Frame: Change from baseline, 16 weeks after treatment starts, 3 months after treatment has ended
|
Global symptom severity and improvement.
Severity of illness scale ranges from 1-7, with higher scores indicating higher severity of illness.
Global improvement scale ranges from 1-7 with lower scores indicating more improvement.
|
Change from baseline, 16 weeks after treatment starts, 3 months after treatment has ended
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Short version of the Experiences in Close Relationships Scale - Revised Child version
Time Frame: Change from baseline, once every second week during treatment (0-12 weeks after baseline)
|
Experiences in close relationships.
Ranges from 12-84, with higher scores indicating greater problems.
|
Change from baseline, once every second week during treatment (0-12 weeks after baseline)
|
|
Generalised Anxiety Disorder 7-item scale
Time Frame: Change from baseline, once every second week during treatment (0-12 weeks after baseline)
|
Worry.
Ranges 0-21, with higher scores indicating more worry.
|
Change from baseline, once every second week during treatment (0-12 weeks after baseline)
|
|
Trimbos/iMTA questionnaire for Costs associated with Psychiatric Illness - Child version
Time Frame: Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended
|
Costs associated with psychiatric illness
|
Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended
|
|
Kidscreen-10
Time Frame: Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended
|
Quality of life.
Ranges 11-55, with higher scores indicating higher quality in life.
|
Change from baseline, 12 weeks after treatment starts, 3 and 12 months after treatment has ended
|
|
Patient Internet-delivered cognitive behavioral Adherence Scale
Time Frame: 6 and 12 weeks after baseline
|
Patient adherence to treatment.
Ranges from 0-20, with higher scores indicating higher adherence.
|
6 and 12 weeks after baseline
|
|
Working Alliance Inventory
Time Frame: 4 weeks after treatment starts
|
Working alliance with online therapist
|
4 weeks after treatment starts
|
|
The Coping with Children's Negative Emotions Scale Adolescent Version
Time Frame: Change from baseline, 6 and 12 weeks after treatment starts, 3 and 12 months after treatment has ended
|
Parents' perceived ability to cope with children's negative emotions.
Three subscales will be used derived to reflect the specific types of coping response parents tend to use in these situations (punitive reactions, problem focused reactions, and minimization reactions).
Each subscale ranges from 1-7.
|
Change from baseline, 6 and 12 weeks after treatment starts, 3 and 12 months after treatment has ended
|
|
The Client Satisfaction Questionnaire
Time Frame: 12 weeks after treatment starts
|
Client satisfaction with treatment.
Ranges from 8-32 with higher scores indicating greater treatment satisfaction.
|
12 weeks after treatment starts
|
|
Adverse Events
Time Frame: 12 weeks after treatment starts
|
Self-rating scale that measures adverse events related to treatment
|
12 weeks after treatment starts
|
|
Credibility/Expectancy Questionnaire
Time Frame: 1 week after treatment starts
|
Treatment credibility and expectancy.
Ranges from 0-50 with higher scores indicating greater credibility/expectancy.
|
1 week after treatment starts
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Clara Hellner, PhD, MD, Karolinska Institutet
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017/10 BIP ERITA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nonsuicidal Self-injury
-
Seoul National University HospitalWhanin Pharmaceutical CompanyNot yet recruitingNonsuicidal Self-InjurySouth Korea
-
Karolinska InstitutetCompletedNonsuicidal Self-InjurySweden
-
University of Electronic Science and Technology...RecruitingNonsuicidal Self Injury | Prediction ErrorsChina
-
University of Electronic Science and Technology...RecruitingNonsuicidal Self Injury | Risk-TakingChina
-
Southern Methodist UniversityCompletedAnxiety | Nonsuicidal Self-InjuryUnited States
-
University of Electronic Science and Technology...RecruitingEmotion Regulation | Nonsuicidal Self InjuryChina
-
Region ÖstergötlandRecruitingEmotion Regulation | Nonsuicidal Self InjurySweden
-
Karolinska InstitutetCompletedNonsuicidal Self-InjurySweden
-
Karolinska InstitutetVastra Gotaland Region; Region Skane; Region StockholmRecruitingSelf-Harm | Nonsuicidal Self-InjurySweden
-
Northwestern UniversityCompletedDepression | Anxiety | Suicidal Ideation | Nonsuicidal Self InjuryUnited States
Clinical Trials on Emotion regulation individual therapy
-
Karolinska InstitutetCompletedNonsuicidal Self-InjurySweden
-
Karolinska InstitutetCompletedNonsuicidal Self-InjurySweden
-
University of California, IrvineMemorial Sloan Kettering Cancer CenterUnknown
-
Mental Health Services in the Capital Region, DenmarkRegion of Southern Denmark; Copenhagen Trial Unit, Center for Clinical Intervention... and other collaboratorsRecruiting
-
Teachers College, Columbia UniversityRecruitingDepression | Anxiety | Distress, Emotional | Rumination | Self-Criticism | WorryUnited States
-
Douglas MenninWeill Medical College of Cornell University; Kent State UniversityCompletedGeneralized Anxiety Disorder | Depression, Anxiety | Anxiety Disorders and Symptoms | Emotional DysfunctionUnited States
-
Teachers College, Columbia UniversityActive, not recruitingDepression | Anxiety | Distress, Emotional | Rumination | Self-Criticism | WorryUnited States
-
Teachers College, Columbia UniversityUniversity of MichiganCompletedDepression | Anxiety | Distress, Emotional | Emotional DysfunctionUnited States
-
Mental Health Services in the Capital Region, DenmarkKarolinska Institutet; Copenhagen Trial Unit, Center for Clinical Intervention...CompletedNon-suicidal Self-injuryDenmark
-
University of AarhusCompletedAnxiety DepressionDenmark